Lexicon Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company...
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06481891
- Locations
- 🇺🇸
Lexicon Investigation Site (4037), Scottsdale, Arizona, United States
🇺🇸Lexicon Investigation Site (4035), Pomona, California, United States
🇺🇸Lexicon Investigational Site (4024), Tulsa, Oklahoma, United States
A Dose-ranging Study in Patients with Diabetic Peripheral Neuropathic Pain (DPNP)
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 416
- Registration Number
- NCT06203002
- Locations
- 🇺🇸
Lexicon Investigational Site (128), Anniston, Alabama, United States
🇺🇸Lexicon Investigational Site (222), Birmingham, Alabama, United States
🇺🇸Lexicon Investigational Site (189), Daphne, Alabama, United States
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT04662281
- Locations
- 🇨🇿
Lexicon Investigational Site (138), Choceň, Czechia
🇵🇱Lexicon Investigational Site (133), Warsaw, Poland
🇨🇿Lexicon Investigational Site (141), Praha, Czechia
Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 319
- Registration Number
- NCT04455633
- Locations
- 🇺🇸
Lexicon Investigational Site (156), Chandler, Arizona, United States
🇺🇸Lexicon Investigational Site (162), Kingman, Arizona, United States
🇺🇸Lexicon Investigational Site (149), Greenville, South Carolina, United States
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 1222
- Registration Number
- NCT03521934
- Locations
- 🇺🇸
Investigational Site Number 8400057, Port Charlotte, Florida, United States
🇺🇸Investigational Site Number 8400095, Maumee, Ohio, United States
🇺🇸Investigational Site Number 8400115, Philadelphia, Pennsylvania, United States
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT03423446
- Locations
- 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT03386344
- Locations
- 🇨🇦
Investigational Site Number 1249003, Brampton, Canada
🇨🇦Investigational Site Number 1249005, Pointe-Claire, Canada
🇨🇦Investigational Site Number 1249007, Vancouver, Canada
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 770
- Registration Number
- NCT03351478
- Locations
- 🇺🇸
Investigational Site Number 8408010, Knoxville, Tennessee, United States
🇺🇸Investigational Site Number 8408038, Knoxville, Tennessee, United States
🇧🇬Investigational Site Number 1008005, Ruse, Bulgaria
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 954
- Registration Number
- NCT03332771
- Locations
- 🇺🇸
Investigational Site Number 8407074, Bradenton, Florida, United States
🇺🇸Investigational Site Number 8407111, Dallas, Texas, United States
🇺🇸Investigational Site Number 8407078, Carmichael, California, United States
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
- Conditions
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 10584
- Registration Number
- NCT03315143
- Locations
- 🇧🇬
Investigational Site Number 1000014, Silistra, Bulgaria
🇺🇸Investigational Site Number 8400104, Chicago, Illinois, United States
🇺🇸Investigational Site Number 8400001, Chicago, Illinois, United States